Published on July 22, 2025
Vergés & Associates v. MegaCorp - Class Action Settlement
Achieved favorable $45M settlement in nationwide class action against pharmaceutical company for misleading drug marketing.
Client
Vergés & Associates (Class Counsel)
Practice
litigation
Jurisdiction
U.S. District Court (Southern District of New York)
Value
$45M settlement
Result
$45 million settlement approved by court, benefiting 50,000+ class members.
Category
Class Action
Meet the legal team
Attorneys Involved
Our attorneys bring deep expertise and dedication to every case. Learn more about the professionals who guided this matter to a successful resolution, each contributing specialized skills and strategic insight to deliver results for our client.
Leandro Quintana
Litigation Partner
Chicago Office
Ragnhild Aasland
Family Law Associate
Washington, DC Office
Client Testimonial
Lead Plaintiff"This settlement provides real relief to thousands of patients who were harmed by misleading drug claims."
Case Overview
Vergés & Associates filed a nationwide class action lawsuit against MegaCorp Pharmaceuticals, alleging that the company engaged in deceptive marketing practices for their blockbuster diabetes medication. The complaint claimed that MegaCorp overstated the drug’s effectiveness while downplaying serious side effects.
Allegations
- False advertising regarding clinical trial results
- Misrepresentation of drug safety profile
- Failure to disclose known side effects
- Targeted marketing to vulnerable patient populations
Litigation Process
- Class Certification: Successfully certified a class of 50,000+ patients who purchased the medication
- Discovery: Extensive document production and deposition testimony revealed internal company communications acknowledging the misleading claims
- Mediation: Multiple mediation sessions led to a comprehensive settlement agreement
Settlement Terms
The $45 million settlement provides:
- Cash payments to class members based on usage and harm
- Medical monitoring program for at-risk patients
- Corrective advertising campaign
- Establishment of patient education fund
Court Approval
After thorough review, the district court approved the settlement as fair, reasonable, and adequate. The settlement has been praised by consumer advocacy groups for providing meaningful relief to affected patients.
Broader Impact
This case contributes to ongoing efforts to hold pharmaceutical companies accountable for truthful marketing and patient safety.